

Special Issue

Regenerative Ophthalmology: From Molecular Basis to Therapy

Message from the Guest Editors

During the last decade, research on ophthalmology has been taking huge leaps forward by uncovering new avenues for clinical applications. With the recent advancements in genomic and molecular medicine, the pathologies hindering sight have never been so thoroughly described, helping clinicians to diagnose and treat patients earlier and faster than ever before. In the scope of this issue, we are presenting an overview of the advancements in the field.

The development of new technologies, such as single-cell resolution -omics, or gene therapy, together with a deeper understanding over the genome and how its organization impacts cellular pathophysiology, provide scientists with a perfect momentum to unravel biological mechanisms underlying pathologies and swiftly propose new clinical avenues to treat affected patients.

This Special Issue of *Biomedicines* aims at highlighting these new findings, their impacts on disease management, and novel treatment discoveries which aim to retain or even regain sight. In this context, this Special Issue also deciphers the future of the general direction of visual science and tomorrow's challenges but also possibilities in ocular medicine.

Guest Editors

Dr. Frederic Michon

Institute for Neurosciences of Montpellier, 34295 Montpellier, France

Dr. Paolo Boffano

Division of Maxillofacial Surgery, University Hospital "Maggiore della Carità", University of Eastern Piedmont, 28100 Novara, Italy

Deadline for manuscript submissions

closed (30 September 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/93822

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).